Distributor inventory | Tablet
Glimepiride 1 mg + Metformin (as Metformin Hydrochloride) 500 mg + Voglibose 0.2 mg
Type 2 diabetes mellitus (adult) when blood sugar is not adequately controlled with diet/exercise and single/dual oral therapy; helps control both fasting and post-meal blood glucose.
Glimepiride (a sulfonylurea) increases insulin release from the pancreas. Metformin (a biguanide) reduces glucose production in the liver and improves insulin sensitivity. Voglibose (an alpha‑glucosidase inhibitor) slows carbohydrate digestion/absorption in the intestine, reducing post‑meal glucose spikes.
Oral tablet. Take exactly as prescribed, usually once daily with/after food (commonly with the main meal) to reduce stomach upset and low sugar risk; swallow whole with water. Do not skip meals; monitor blood glucose as advised.
Common side effects of AZULIX MV 1/0.2 TAB may include:
Prescription-only antidiabetic. Risk of hypoglycaemia (higher if meals are skipped, with excess exercise, alcohol, or other antidiabetics); carry glucose/sugar. Metformin can rarely cause lactic acidosis—seek urgent care for severe weakness, muscle pain, breathing difficulty, abdominal discomfort, or drowsiness; avoid in severe kidney impairment and use caution in liver disease/heart failure. Temporarily stop metformin before/after iodinated contrast studies and major surgery as advised. Voglibose may cause gas/diarrhoea; use caution in inflammatory bowel disease, intestinal obstruction, or chronic intestinal disorders. Regular monitoring of kidney function, HbA1c, and vitamin B12 (long-term metformin) is advised.
